For the best experience we recommend upgrading to the latest version of these supported browsers:
I wish to continue viewing on my unsupported browser
For the best experience we recommend upgrading to the latest version of these supported browsers:
I wish to continue viewing on my unsupported browser
13 January 2021
New York—NERA Economic Consulting supported Schönherr, the leading Austrian law firm, to provide economic analysis, damage quantification, and testimony in an arbitration involving Schönherr’s client AOP Orphan Pharmaceuticals AG (“AOP”), an Austrian pharmaceutical company specializing in the treatment of rare diseases, against Taiwanese biopharmaceutical company PharmaEssentia Corporation.
The dispute arose over the development and commercialization of a new orphan drug called BESREMi® (for treatment of rare blood cancer diseases). By agreement with PharmaEssentia, AOP had completed the clinical and regulatory development of BESREMi® in the European Union and had exclusive distribution rights for commercializing BESREMi® in Europe and the Middle East. PharmaEssentia, as the patent owner and licensor of BESREMi®, tried to terminate the underlying agreement with AOP. AOP did not accept that termination and started arbitration proceedings against PharmaEssentia, claiming damages for late commercialization due to PharmaEssentia’s uncooperative behavior.
As part of the case led by Schönherr, NERA’s Frankfurt-based Managing Director Dr. Yves Hervé and his team—including Dr. Georg Siegert and Fabian Peters—were hired as economic experts for AOP to calculate the quantum of damages. Dr. Hervé testified as an expert witness before an arbitration tribunal held under the auspices of the International Chamber of Commerce (ICC).
On Tuesday, 20 October 2020, after two and a half years of arbitration proceedings, the tribunal ruled in favor of Schönherr’s client AOP, who was awarded approximately 143 million euros in damages. The damage calculation was based on NERA’s economic modelling.
About NERA
NERA Economic Consulting (www.nera.com) is a global firm of experts dedicated to applying economic, finance, and quantitative principles to complex business and legal challenges. For more than six decades, we have been creating strategies, studies, reports, expert testimony, and policy recommendations for government authorities and the world’s leading law firms and corporations. We bring academic rigor, objectivity, and real-world industry experience to issues arising from competition, regulation, public policy, strategy, finance, and litigation.
NERA’s clients value our ability to apply and communicate state-of-the-art approaches clearly and convincingly, our commitment to deliver unbiased findings, and our reputation for quality and independence. Our clients rely on the integrity and skills of our unparalleled team of economists and other experts backed by the resources and reliability of one of the world’s largest economic consultancies. Continuing our legacy as the first international economic consultancy, NERA serves clients from major cities across North America, Europe, and Asia Pacific.